Applications sent by 2 vaccine makers with drug controller, experts being studied pro-actively: Dr Harsh Vardhan

Published On 2021-01-01 12:00 GMT   |   Update On 2021-01-01 12:33 GMT
Advertisement

New Delhi: A day ahead of pan-India dry-run for Covid-19 vaccine, Union Health and Family Affairs Minister Dr Harsh Vardhan on Friday said that at least two vaccine makers have sent their applications to drug controller and experts for approval and their data is being studied pro-actively.

The Union Health Minister made the remarks while holding a review meeting with the Delhi government for the preparation of the crucial programme, a day before the dry-run of the Covid-19 vaccine.

Advertisement

The dry-run will be conducted by all the state and union territory governments on January 2 to test the linkages between planning and implementation and to identify the challenges, the Centre said on Thursday. The activity is proposed to be conducted in all state capitals in at least three session sites.

The minister said that the lists of health workers have been created and will be uploaded on Covid-19 platform. "Just like we prepare during elections, the same way we need to train each member of all medical teams responsibly," the Union Minister said.

He further said that the target of this exercise is that "minutest details" are thoroughly researched.

"At least two vaccine makers have sent their applications to drug controller and experts for approval, their data are being studied pro-actively," he said.

Read also: Pfizer, SII, Bharat Biotech seek emergency use authorization for COVID vaccines: CDSCO panel to reconvene on Jan 1

He further said that after training over 2,000 master trainers at the national level, the training is underway at State and district level, in over 700 districts.

"The procedure is similar to conducting elections where the team at a booth is also trained," he added.

Read also: Serum Institute unveils India first fully indigenous pneumococcal vaccine



Tags:    
Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News